BIPOC involvement in oncological research: insights from Future Oncology

In this special edition of editor’s highlights, Michael Bell, Managing Editor at Taylor & Francis Group, looks at three articles published over the last 12 months in Future Oncology, concerning greater engagement and representation for Black, Indigenous and People of Colour (BIPOC) people in oncological research. Efficacy and safety of Darolutamide in Black/African-American patients from Phase III ARAMIS study Nubeqa® (darolutamide) is a potent and selective androgen receptor inhibitor (ARi), which is used as a treatment option for patients with prostate cancer that has stopped responding to androgen deprivation therapy (ADT) but has not metastasized to other parts of the...